Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
Status:
Completed
Trial end date:
2021-07-21
Target enrollment:
Participant gender:
Summary
A Phase 3 study to evaluate efficacy, safety, and tolerability of ampreloxetine (TD-9855) in
subjects with primary autonomic failures (MSA, PD, or PAF) and symptomatic nOH with up to 4
weeks of treatment.